<DOC>
	<DOCNO>NCT02992236</DOCNO>
	<brief_summary>Analysis effect NO-Synthase inhibitor VAS203 ( 6 hour infusion 10 mg/kg ) renal function perfusion 16 healthy subject .</brief_summary>
	<brief_title>Effects NO-synthase Inhibitor VAS203 Renal Function Healthy Volunteers</brief_title>
	<detailed_description>Analysis effect i.v . VAS203 renal function perfusion healthy subject . Primary objective : Possible adverse effect VAS203 Renal Plasma Flow ( RPF ) Glomerular Filtration Rate ( GFR ) 6 hour constant-rate iv . infusion 10 mg/kg VAS203 . Secondary objective : To analyse effect VAS203 - filtration fraction - hemodynamics ( afferent efferent resistance , intraglomerular pressure ) - marker kidney injury renal function - systolic , mean diastolic brachial blood pressure - Plasma PK VAS203 first metabolite .</detailed_description>
	<criteria>1 . Informed consent write available . 2 . Willing able comply requirement study . 3 . Male , 18 45 year ( inclusive ) . 4 . Subject body weight 60 kg 100 kg , extremes include . 5 . BMI 18 27 kg/m2 . 6 . Nonsmoker 7 . Serum creatinine within reference range ( â‰¤1.2 mg/dL ) CockroftGault Clearance &gt; 90 ml/min 8 . Good general health judge Investigator , determine medical history , physical examination , vital sign ( systolic diastolic blood pressure pulse rate ) clinical laboratory parameter ( clinical chemistry , hematology , urinalysis ) 1 . Clinically significant abnormality physical examination , vital sign clinical laboratory parameter ( accord Investigator 's judgment ) . 2 . SGOT SGPT level &gt; 2times upper limit normal range . 3 . Subject CockroftGault clearance &lt; 90 ml/min . 4 . Clinically significant history cardiovascular disease know present cardiovascular disease . 5 . History clinically significant neurological , gastrointestinal , renal , hepatic , psychological , pulmonary , metabolic , endocrine , hematological , major disorder . 6 . Office blood pressure screen high 160/100 mmHg , low 95/55 mmHg . 7 . Office heart rate screen least 5 minute outside range 50 99 beat per minute ( inclusive ) . 8 . Concomitant use OTC medication within 1 week prior dosing , except use paracetamol ( 2 g/day ) . 9 . Participation clinical study within 30 day prior inclusion</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>